• Home
  • Guidance and Case Studies
  • Classics
  • About Us
  • e-Newsletter

Advert
  • Expert Insights
  • Readers' Choice
  • Resources
  • Audio & Video
    • Featured
  • QbD News
  • Opinion Editorial

Classics

  • Share

Classic Articles

Quality by Design for Biopharmaceuticals

An Executive’s Guide to Quality by Design

Why QbD Should Be on the Executive Team’s Agenda

Implementing Quality by Design: Are You Ready or Not?

Design for Six Sigma: A Potent Supplement to QbD

PAT and Green Chemistry: The Intersection of Benign by Designand Quality by Design

BioProcess Control: What the Next 15 Years Will Bring

On the More Technical Side

QbD for Better Method Validation and Transfer at GSK

A Quality-by-Design Methodology for Rapid LC Method Development, Part I, Part II, and Part III

What Your ICH Q8 Design Space Needs: A Multivariate Predictive Distribution

QbD Using a Gaussian Mixture Density Approximation of Biological Uncertainties

Using Design of Experiments to Optimize Chiral Separation

Utilizing Mechanistic and Empirical Modeling at BMS

Videos, etc.

Videos: Reaction Monitoring Via Spectroscopy at Pfizer

Have suggestions for this page? Email pthomas@putman.net.

  • Latest
  • Comments
  • Tags
  • Subscribe
  • Profitability, Integrity and the Cost of Poor Pharma Quality Profitability, Integrity and the Cost of Poor Pharma Quality
  • FDA’s Friedman’s Challenge to Pharma Execs:  Modernize! FDA’s Friedman’s Challenge to Pharma Execs: Modernize!
  • Control, Innovation and the Consumer: Keys to a Different Drug Industry Control, Innovation and the Consumer: Keys to a Different Drug Industry
  • Memoirs from IFPAC 2012 Memoirs from IFPAC 2012
  • Sampling at IFPAC: Will Pharma Move to Large N? Sampling at IFPAC: Will Pharma Move to Large N?
  • Unfinished Business Unfinished Business
  • Quality Risk Management: 16 FAQ’s to Chew On Quality Risk Management: 16 FAQ's to Chew On
  • Continuous Manufacturing in Pharma: Beginning to Snowball? Continuous Manufacturing in Pharma: Beginning to Snowball?
  • Arrogance, Ignorance, and Fear: Too Much for QbD to Overcome? Arrogance, Ignorance, and Fear: Too Much for QbD to Overcome?
  • In-line Particle Sizing: A PAT Solution for High Shear Granulation In-line Particle Sizing: A PAT Solution for High Shear Granulation
  • epcotint: Siegfried: Answer is simple. The presentation d...
  • epcotint: Everyone wants to take the horse to the pond but t...
  • siegfried: It is still beyond comprehension why none of the p...
  • zasmine: This is agreat article AMS! Thank you for the int...
  • epcotint: McKinsey report points to different challenges com...
AIChE Ali Afnan analytical methods Bikash Chatterjee biopharmaceutical QbD bioprocess control BMS CDER continuous manufacturing design of experiments design space drug development DynoChem Eli Lilly Emerson Process Management Emil Ciurczak fda Gawayne Mahboubian-Jones Girish Malhotra GSK guidance documents helen winkle ICH ICH Q8 IFPAC ISPE Joe Hannon Lean Six Sigma Merck modeling Moheb Nasr Novartis operational excellence PAT PDA Pedro Hernandez Pfizer pharmacutical quality process control process understanding process validation qbd risk management time to market Toyota
  • Stay up to date

  • Subscribe to the RSS feed
  • Subscribe to PharmaQbD by Email

Popular Posts

  • Continuous Manufacturing in Pharma: Beginning to Snowball? 5 comment(s)
  • In-line Particle Sizing: A PAT Solution for High Shear Granulation 4 comment(s)
  • Going with the Flow: Advancing Continuous Drug Synthesis 3 comment(s)
  • Moving Beyond the Business Case for QbD 3 comment(s)
  • Do We Need PAT and QbD Anymore? 2 comment(s)

QbD Links

  • Chemical Research, Development and Scale-up
  • Design Space and QbD Blog
  • dTC's Quality by Design Blog (Spanish)
  • Emerson Global Life Sciences Blog
  • FDA Homepage
  • ICH Homepage
  • Innovative Medicines Initiative
  • International Pharmaceutical Quality
  • Maxiom Group Blog
  • Mining Drug Space
  • On Pharma Blog
  • Pharmaceutical Manufacturing
  • QA Pharm
  • QbD Viewpoint

Twitterfeed

  • Best of Funny Pharm on Pinterest. What do you think? Is Pinterest a tool for our industry? http://t.co/LdDvZujm #pharma #interphex www.twitter.com/PharmaQbD
  • IFPAC 2012: The Club Opens Up: if this conference was any indication, maybe more people are starting to see the ... http://t.co/wZWo8DuE www.twitter.com/PharmaQbD
  • Case Studies: Multivariate Analysis at Novartis: A new article sheds light on how Novartis is using PAT tools an... http://t.co/t9XbcjuY www.twitter.com/PharmaQbD
  • Can Regulatory Harmonization Be More Effective, and Equitable?: A new not-for-profit will champion global regula... http://t.co/KlyAdfdh www.twitter.com/PharmaQbD

AIChE Ali Afnan analytical methods Bikash Chatterjee biopharmaceutical QbD bioprocess control BMS CDER continuous manufacturing design of experiments design space drug development DynoChem Eli Lilly Emerson Process Management Emil Ciurczak fda Gawayne Mahboubian-Jones Girish Malhotra GSK guidance documents helen winkle ICH ICH Q8 IFPAC ISPE Joe Hannon Lean Six Sigma Merck modeling Moheb Nasr Novartis operational excellence PAT PDA Pedro Hernandez Pfizer pharmacutical quality process control process understanding process validation qbd risk management time to market Toyota

WP Cumulus Flash tag cloud by Roy Tanck and Luke Morton requires Flash Player 9 or better.

© 2008-2012 PharmaQbD. Powered by Wordpress.

Website by The WordPress Guy